News › Industry News, Patient Care, Practice Management

FDA Announces Semaglutide Shortage Resolved

February 24, 2025

On February 21, 2025, the FDA announced that the shortage of semaglutide has been resolved due to increased manufacturing capacity. This follows the recent resolution of the tirzepatide shortage (link here). To prevent disruption to patient care, the FDA will not take enforcement action against compounders for certain violations related to compounding semaglutide until April 22, 2025, for pharmacies and until May 22, 2025, for outsourcing facilities. The FDA is also monitoring the availability of other GLP-1 medications, including dulaglutide and liraglutide, which remain in shortage.

In the short term, before the FDA’s deadlines, these compounded medications should still be available. However, practices should start reviewing and updating their weight loss programs to prepare for after these deadlines pass. AmSpa had this article and ByrdAdatto had this article on things to consider when the shortages are over. You may also want to speak with an attorney for guidance on your particular situation.  

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Allergan Aesthetics’ Skinvive by Juvéderm Receives FDA Approval for the Improvement of Neck Appearance
    • Obagi Medical Announces FDA Approval of Obagi saypha ChIQ Injectable Hyaluronic Acid Gel
    • MedSafe Becomes Gold Vendor Affiliate with the American Med Spa Association
    • FDA Approves First New Sunscreen Ingredient in 20 Years
    • Allergan Aesthetics Releases ‘The Aesthetics Evolution: What Consumers Really Want’ Highlighting Consumer Motivations and Expectations in Aesthetics